A weekly trade journal catering to the Indian chemical industry
backBack

calendar 13 March, 2026 15:07:05 IST

Samsung Biologics and Lilly to set up ‘gateway lab’ to support Korean biotech startups

Article image

Samsung Biologics, a Korean contract development and manufacturing organisation (CDMO), has announced a collaboration agreement with US-based pharma major, Eli Lilly and Company, to establish a Lilly Gateway Labs (LGL) site in Korea.

The LGL site will serve as a hub to support early-stage and emerging biotechnology companies, as they advance scientific research toward development and manufacturing. The facility will feature flexibly designed laboratory space and research infrastructure, collaborative space, and operational support, with capacity for up to 30 companies jointly selected by Lilly and Samsung.

Under the collaboration agreement, Samsung Biologics will develop and operate the new facility, with LGL providing customised scientific engagement to support resident biotech companies and catalyse collaboration across the Korea life sciences sector. Located within Samsung Biologics’ Bio Campus II site, the facility will comprise five stories and is expected to be completed in July 2027.

Beyond supporting individual companies, the site is expected to contribute to Korea’s broader biotechnology ecosystem by attracting global innovation activity, fostering talent development, and strengthening the country’s position as a hub for early-stage life science research. By connecting domestic and international biotech startups with global industry expertise, the initiative aims to accelerate the translation of scientific discovery into development and manufacturing within Korea, supporting long-term growth of the national bio-industry.

The LGL model is designed to enable resident companies to accelerate drug discovery and development by combining infrastructure and connecting company founders and scientists with Lilly’s global network of experts. LGL is part of ‘Lilly Catalyze360’, which supports biotech innovation by providing access to strategic capital, lab space and technology, and R&D capabilities. Since the first Gateway Labs site opened in 2019, resident companies have collectively raised more than $3-bn, fuelling progress on over 50 therapeutic programmes, the companies said.

Dr. Julie Gilmore, Vice President, and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management, said, “Korea has emerged as a vibrant centre for life sciences innovation with exceptional scientific talent. By establishing Gateway Labs here, we are creating a hub where early-stage companies can access the resources, expertise, and connections needed to accelerate their journey from discovery to development, strengthening both local and global biotech innovation.”

article image
calender image

calender image 2 November, 2026 18:04:08 IST

AI for supply chain resilience in chemicals is here

Chemical supply chains now operate as “integrated decision networks,” where production planning, demand forecasting, inventory optimisation, transportation capacity, po...
article image

calender image 6 November, 2026 16:01:05 IST

Grasim, Suzlon team up to pilot chemically recyclable wind turbine blades

Mumbai-based Grasim Industries, a diversified Aditya Birla Group company with businesses in cellulosic fibres, chemicals and...

PRINT EDITION

View Past Issues

Search For

Exhibitions & Conferences

ChemExpo IndiaChemProTechChemLogistics India

Watch

KKBangEchemiAPi ChinaGPCA ForumCPHI PMEC INDIA